Brean Capital Cuts Ligand Pharma (LGND) to Hold on Valuation

October 31, 2013 7:37 AM

Brean Capital downgraded Ligand Pharma (NASDAQ: LGND) from Buy to Hold. The change relates to valuation.

"Based on our ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found